Okoli Tracy C, Peer Cody J, Dunleavy Kieron, Figg William D
a Clinical Pharmacology Program; Center for Cancer Research ; National Cancer Institute , Bethesda , MD USA.
Cancer Biol Ther. 2015;16(2):204-6. doi: 10.1080/15384047.2014.1002369.
Indolent Non-Hodgkin Lymphomas (iNHL) are typically B-cell malignancies and are incurable with current standard approaches. Thus, there is a demand for novel agents specific for this group of disorders. In a phase II study published by Gopal et al. in the New England Journal of Medicine, idelalisib, a small molecule inhibitor of PI3Kδ that was FDA approved in July of 2014, was shown to be effective when combined with rituximab in patients who cannot tolerate chemotherapy and as last line therapy in patients with iNHL refractory to 2 prior systemic therapies. Idelalisib demonstrated tolerable diarrhea, fatigue, nausea, pyrexia, and cough. While this novel agent is a clinically significant addition to the iNHL arsenal, further research is needed to determine its most appropriate place in iNHL therapy.
惰性非霍奇金淋巴瘤（iNHL）通常是B细胞恶性肿瘤，采用当前的标准方法无法治愈。因此，需要针对这类疾病的新型药物。在戈帕尔等人发表于《新英格兰医学杂志》的一项II期研究中，idelalisib（一种PI3Kδ小分子抑制剂，于2014年7月获得美国食品药品监督管理局批准）与利妥昔单抗联合使用时，对无法耐受化疗的患者以及对先前两种全身治疗均难治的iNHL患者作为最后一线治疗显示出有效性。Idelalisib表现出可耐受的腹泻、疲劳、恶心、发热和咳嗽。虽然这种新型药物是iNHL治疗手段中具有临床意义的补充，但仍需要进一步研究以确定其在iNHL治疗中最合适的位置。
